1. Siegel RL, Miller KD, Fuchs HE, Jemal A: Cancer Statistics, 2021. CA: A Cancer Journal for Clinicians2021, 71(1):7-33.
2. Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M, Cutter D, Davies C, Ewertz M, Godwin Jet al: Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet2011, 378(9804):1707-1716.
3. McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, Gray R, Mannu G, Peto R, Whelan Tet al: Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet2014, 383(9935):2127-2135.
4. Pignol JP, Olivotto I, Rakovitch E, Gardner S, Sixel K, Beckham W, Vu TT, Truong P, Ackerman I, Paszat L: A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol2008, 26(13):2085-2092.
5. Collette S, Collette L, Budiharto T, Horiot JC, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet A, Jager JJ, Hoogenraad Wet al: Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: a study based on the EORTC Trial 22881-10882 'boost versus no boost'. Eur J Cancer2008, 44(17):2587-2599.
6. Speers C, Pierce LJ: Postoperative Radiotherapy After Breast-Conserving Surgery for Early-Stage Breast Cancer: A Review. JAMA Oncol2016, 2(8):1075-1082.
7. Díaz-Gavela AA, Figueiras-Graillet L, Luis Á M, Salas Segura J, Ciérvide R, Del Cerro Peñalver E, Couñago F, Arenas M, López-Fernández T: Breast Radiotherapy-Related Cardiotoxicity. When, How, Why. Risk Prevention and Control Strategies. Cancers (Basel)2021, 13(7).
8. Henson KE, McGale P, Darby SC, Parkin M, Wang Y, Taylor CW: Cardiac mortality after radiotherapy, chemotherapy and endocrine therapy for breast cancer: Cohort study of 2 million women from 57 cancer registries in 22 countries. Int J Cancer2020, 147(5):1437-1449.
9. Taylor CW, Kirby AM: Cardiac Side-effects From Breast Cancer Radiotherapy. Clin Oncol (R Coll Radiol)2015, 27(11):621-629.
10. Smith AW, Reeve BB, Bellizzi KM, Harlan LC, Klabunde CN, Amsellem M, Bierman AS, Hays RD: Cancer, comorbidities, and health-related quality of life of older adults. Health Care Financ Rev2008, 29(4):41-56.
11. Ng HS, Vitry A, Koczwara B, Roder D, McBride ML: Patterns of comorbidities in women with breast cancer: a Canadian population-based study. Cancer Causes Control2019, 30(9):931-941.
12. Gupta SC, Kunnumakkara AB, Aggarwal S, Aggarwal BB: Inflammation, a Double-Edge Sword for Cancer and Other Age-Related Diseases. Front Immunol2018, 9:2160.
13. Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell2011, 144(5):646-674.
14. Asegaonkar SB, Asegaonkar BN, Takalkar UV, Advani S, Thorat AP: C-Reactive Protein and Breast Cancer: New Insights from Old Molecule. Int J Breast Cancer2015, 2015:145647.
15. Guo L, Liu S, Zhang S, Chen Q, Zhang M, Quan P, Lu J, Sun X: C-reactive protein and risk of breast cancer: A systematic review and meta-analysis. Sci Rep2015, 5:10508.
16. Frydenberg H, Thune I, Lofterod T, Mortensen ES, Eggen AE, Risberg T, Wist EA, Flote VG, Furberg AS, Wilsgaard Tet al: Pre-diagnostic high-sensitive C-reactive protein and breast cancer risk, recurrence, and survival. Breast Cancer Res Treat2016, 155(2):345-354.
17. Sicking I, Edlund K, Wesbuer E, Weyer V, Battista MJ, Lebrecht A, Solbach C, Grinberg M, Lotz J, Hoffmann Get al: Prognostic influence of pre-operative C-reactive protein in node-negative breast cancer patients. PLoS One2014, 9(10):e111306.
18. Hu JJ, Urbanic JJ, Case LD, Takita C, Wright JL, Brown DR, Langefeld CD, Lively MO, Mitchell SE, Thakrar Aet al: Association Between Inflammatory Biomarker C-Reactive Protein and Radiotherapy-Induced Early Adverse Skin Reactions in a Multiracial/Ethnic Breast Cancer Population. J Clin Oncol2018, 36(24):2473-2482.
19. Rodriguez-Gil JL, Takita C, Wright J, Reis IM, Zhao W, Lally BE, Hu JJ: Inflammatory biomarker C-reactive protein and radiotherapy-induced early adverse skin reactions in patients with breast cancer. Cancer Epidemiol Biomarkers Prev2014, 23(9):1873-1883.
20. Li Y, Zhong X, Cheng G, Zhao C, Zhang L, Hong Y, Wan Q, He R, Wang Z: Hs-CRP and all-cause, cardiovascular, and cancer mortality risk: A meta-analysis. Atherosclerosis2017, 259:75-82.
21. Raphael MJ, Robinson A, Booth CM, O’Donnell J, Palmer M, Eisenhauer E, Brundage M: The Value of Progression-Free Survival as a Treatment End Point Among Patients With Advanced Cancer: A Systematic Review and Qualitative Assessment of the Literature. JAMA Oncology2019, 5(12):1779-1789.
22. Lee E, Nelson OL, Puyana C, Takita C, Wright JL, Zhao W, Reis IM, Lin RY, Hlaing WM, Bakalar JLet al: Association between C-reactive protein and radiotherapy-related pain in a tri-racial/ethnic population of breast cancer patients: a prospective cohort study. Breast Cancer Res2019, 21(1):70.
23. Lee E, Takita C, Wright JL, Reis IM, Zhao W, Nelson OL, Hu JJ: Characterization of risk factors for adjuvant radiotherapy-associated pain in a tri-racial/ethnic breast cancer population. Pain2016, 157(5):1122-1131.
24. Wright JL, Takita C, Reis IM, Zhao W, Lee E, Nelson OL, Hu JJ: Prospective evaluation of radiation-induced skin toxicity in a race/ethnically diverse breast cancer population. Cancer Med2016, 5(3):454-464.
25. Myers GL, Rifai N, Tracy RP, Roberts WL, Alexander RW, Biasucci LM, Catravas JD, Cole TG, Cooper GR, Khan BVet al: CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the laboratory science discussion group. Circulation2004, 110(25):e545-549.
26. Villaseñor A, Flatt SW, Marinac C, Natarajan L, Pierce JP, Patterson RE: Postdiagnosis C-reactive protein and breast cancer survivorship: findings from the WHEL study. Cancer Epidemiol Biomarkers Prev2014, 23(1):189-199.
27. Contal C, O'Quigley J: An application of changepoint methods in studying the effect of age on survival in breast cancer. Computational Statistics & Data Analysis1999, 30(3):253-270.
28. Ogłuszka M, Orzechowska M, Jędroszka D, Witas P, Bednarek AK: Evaluate Cutpoints: Adaptable continuous data distribution system for determining survival in Kaplan-Meier estimator. Computer Methods and Programs in Biomedicine2019, 177:133-139.
29. Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DCet al: AJCC Cancer Staging Manual, 8 edn: Springer International Publishing; 2017.
30. Jamal O, Aneni EC, Shaharyar S, Ali SS, Parris D, McEvoy JW, Veledar E, Blaha MJ, Blumenthal RS, Agatston ASet al: Cigarette smoking worsens systemic inflammation in persons with metabolic syndrome. Diabetol Metab Syndr2014, 6:79.
31. Tonstad S, Cowan JL: C-reactive protein as a predictor of disease in smokers and former smokers: a review. Int J Clin Pract2009, 63(11):1634-1641.
32. Sollie M, Bille C: Smoking and mortality in women diagnosed with breast cancer-a systematic review with meta-analysis based on 400,944 breast cancer cases. Gland Surg2017, 6(4):385-393.
33. Osimo EF, Baxter L, Stochl J, Perry BI, Metcalf SA, Kunutsor SK, Laukkanen JA, Wium-Andersen MK, Jones PB, Khandaker GM: Longitudinal association between CRP levels and risk of psychosis: a meta-analysis of population-based cohort studies. NPJ Schizophr2021, 7(1):31.
34. Ridker PM: A Test in Context: High-Sensitivity C-Reactive Protein. J Am Coll Cardiol2016, 67(6):712-723.
35. Farmer HR, Wray LA, Xian Y, Xu H, Pagidipati N, Peterson ED, Dupre ME: Racial Differences in Elevated C-Reactive Protein Among US Older Adults. J Am Geriatr Soc2020, 68(2):362-369.
36. Nazmi A, Victora CG: Socioeconomic and racial/ethnic differentials of C-reactive protein levels: a systematic review of population-based studies. BMC Public Health2007, 7:212.
37. Kim J, Jeong K, Lee S, Baek Y: Relationship between Low Vegetable Consumption, Increased High-Sensitive C-Reactive Protein Level, and Cardiometabolic Risk in Korean Adults with Tae-Eumin: A Cross-Sectional Study. Evid Based Complement Alternat Med2021, 2021:3631445.
38. Mazidi M, Kengne AP, Mikhailidis DP, Cicero AF, Banach M: Effects of selected dietary constituents on high-sensitivity C-reactive protein levels in U.S. adults. Ann Med2018, 50(1):1-6.
39. Petekkaya I, Aksoy S, Roach EC, Okoh AK, Gecmez G, Gezgen G, Isler DC, Dogan E, Babacan T, Sarici Fet al: Impact of inflammatory markers on the prognosis of patients with operable breast cancer. J buon2014, 19(3):673-680.
40. Petekkaya I, Unlu O, Roach EC, Gecmez G, Okoh AK, Babacan T, Sarici F, Keskin O, Arslan C, Petekkaya Eet al: Prognostic role of inflammatory biomarkers in metastatic breast cancer. J buon2017, 22(3):614-622.
41. Zhou L, Ma S, Balde AI, Han S, Cai Z, Li Z: A Retrospective Propensity Score Matched Study of the Preoperative C-Reactive Protein to Albumin Ratio and Prognosis in Patients with Resectable Non-Metastatic Breast Cancer. Med Sci Monit2019, 25:4342-4352.
42. Nelson SH, Brasky TM, Patterson RE, Laughlin GA, Kritz-Silverstein D, Edwards BJ, Lane D, Rohan TE, Ho GYF, Manson JEet al: The Association of the C-Reactive Protein Inflammatory Biomarker with Breast Cancer Incidence and Mortality in the Women's Health Initiative. Cancer Epidemiol Biomarkers Prev2017, 26(7):1100-1106.
43. Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, Wener MH, Baumgartner KB, Gilliland FD, Sorensen BE, McTiernan Aet al: Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol2009, 27(21):3437-3444.
44. Nieder C, Mannsåker B, Dalhaug A, Pawinski A, Haukland E: Palliative Radiotherapy in Cancer Patients with Increased Serum C-Reactive Protein Level. In Vivo2016, 30(5):581-586.
45. Liu Y, Chen S, Zheng C, Ding M, Zhang L, Wang L, Xie M, Zhou J: The prognostic value of the preoperative c-reactive protein/albumin ratio in ovarian cancer. BMC Cancer2017, 17(1):285.
46. Allin KH, Bojesen SE, Nordestgaard BG: Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol2009, 27(13):2217-2224.
47. Allin KH, Nordestgaard BG, Flyger H, Bojesen SE: Elevated pre-treatment levels of plasma C-reactive protein are associated with poor prognosis after breast cancer: a cohort study. Breast Cancer Res2011, 13(3):R55.
48. Heikkila K, Ebrahim S, Lawlor DA: A systematic review of the association between circulating concentrations of C reactive protein and cancer. J Epidemiol Community Health2007, 61(9):824-833.
49. Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A: Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis2009, 30(7):1073-1081.
50. Verma GR, Thiagarajan S, Gupta R, Kaman L, Das R, Kochhar R, Sinha SK: Thrombocytosis and Raised CRP Levels Predicts Advanced Stage in Esophageal Carcinoma. J Gastrointest Cancer2015, 46(4):350-355.
51. Collado-Hidalgo A, Bower JE, Ganz PA, Cole SW, Irwin MR: Inflammatory biomarkers for persistent fatigue in breast cancer survivors. Clin Cancer Res2006, 12(9):2759-2766.
52. Starkweather AR, Lyon DE, Schubert CM: Pain and inflammation in women with early-stage breast cancer prior to induction of chemotherapy. Biol Res Nurs2013, 15(2):234-241.
53. Mukherjee D, Coates PJ, Lorimore SA, Wright EG: Responses to ionizing radiation mediated by inflammatory mechanisms. J Pathol2014, 232(3):289-299.
54. Hekim N, Cetin Z, Nikitaki Z, Cort A, Saygili EI: Radiation triggering immune response and inflammation. Cancer Lett2015, 368(2):156-163.
55. Koike Y, Miki C, Okugawa Y, Yokoe T, Toiyama Y, Tanaka K, Inoue Y, Kusunoki M: Preoperative C-reactive protein as a prognostic and therapeutic marker for colorectal cancer. J Surg Oncol2008, 98(7):540-544.
56. Lin ZY, Liang ZX, Zhuang PL, Chen JW, Cao Y, Yan LX, Yun JP, Xie D, Cai MY: Intrahepatic cholangiocarcinoma prognostic determination using pre-operative serum C-reactive protein levels. BMC Cancer2016, 16(1):792.
57. Migita K, Matsumoto S, Wakatsuki K, Kunishige T, Nakade H, Miyao S, Sho M: Postoperative Serum C-Reactive Protein Level Predicts Long-term Outcomes in Stage I GastricCancer. J Surg Res2019, 242:323-331.
58. Shibutani M, Maeda K, Nagahara H, Noda E, Ohtani H, Nishiguchi Y, Hirakawa K: Prognostic significance of the preoperative serum C-reactive protein level in patients with stage IV colorectal cancer. Surg Today2015, 45(3):315-321.
59. Shimura T, Shibata M, Gonda K, Murakami Y, Noda M, Tachibana K, Abe N, Ohtake T: Prognostic impact of interleukin-6 and C-reactive protein on patients with breast cancer. Oncol Lett2019, 17(6):5139-5146.
60. Thurner EM, Krenn-Pilko S, Langsenlehner U, Stojakovic T, Pichler M, Gerger A, Kapp KS, Langsenlehner T: The elevated C-reactive protein level is associated with poor prognosis in prostate cancer patients treated with radiotherapy. Eur J Cancer2015, 51(5):610-619.
61. Basu S, Harris H, Larsson A, Vasson MP, Wolk A: Is There Any Role for Serum Cathepsin S and CRP Levels on Prognostic Information in Breast Cancer? The Swedish Mammography Cohort. Antioxid Redox Signal2015, 23(16):1298-1302.
62. Arnold K, Opdenaker L, Flynn N, Appeah D, Sims-Mourtada J: Radiation induces an inflammatory response that results in STAT3-dependent changes in cellular plasticity and radioresistance of breast cancer stem-like cells. International Journal of Radiation Biology2019, 96:1-43.
63. Kong D, Hughes CJ, Ford HL: Cellular Plasticity in Breast Cancer Progression and Therapy. Front Mol Biosci2020, 7:72-72.
64. Reisinger KW, Derikx JP, van Vugt JL, Von Meyenfeldt MF, Hulsewé KW, Olde Damink SW, Stoot JH, Poeze M: Sarcopenia is associated with an increased inflammatory response to surgery in colorectal cancer. Clin Nutr2016, 35(4):924-927.
65. Hayashi T, Furukawa K, Morishita Y, Hayashi I, Kato N, Yoshida K, Kusunoki Y, Kyoizumi S, Ohishi W: Intracellular reactive oxygen species level in blood cells of atomic bomb survivors is increased due to aging and radiation exposure. Free Radic Biol Med2021, 171:126-134.
66. Najafi M, Shirazi A, Motevaseli E, Rezaeyan AH, Salajegheh A, Rezapoor S: Melatonin as an anti-inflammatory agent in radiotherapy. Inflammopharmacology2017, 25(4):403-413.
67. Zhang Z: Too much covariates in a multivariable model may cause the problem of overfitting. J Thorac Dis2014, 6(9):E196-E197.
68. Clark TG, Bradburn MJ, Love SB, Altman DG: Survival analysis part IV: further concepts and methods in survival analysis. Br J Cancer2003, 89(5):781-786.
69. Babyak MA: What You See May Not Be What You Get: A Brief, Nontechnical Introduction to Overfitting in Regression-Type Models. Psychosomatic Medicine2004, 66(3):411-421.